KHINDIVI (Hydrocortisone) Patent Expiration, LOE Window & CMS Spending

KHINDIVI (Hydrocortisone) by Eton: FDA Orange Book core substance LOE 2043-02-23, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $11,423 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEton
FDA Application & PathwayN218980 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2043-02-23
Last Listed Patent or Exclusivity Date2043-02-23
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($11,423 intro WAC)